New biosimilar shows promise for treating wet AMD in Real-World study
NCT ID NCT07235527
First seen Nov 19, 2025 · Last updated Apr 29, 2026 · Updated 20 times
Summary
This study looks at how well a biosimilar drug called MY-1701P (similar to Eylea) works for people with wet age-related macular degeneration, a condition that causes vision loss. About 54 patients will receive the drug and have their vision and eye health checked regularly. The goal is to see if the drug improves vision and reduces fluid buildup in the eye, helping manage the disease over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Prof. Dr. Cemil Taşcıoğlu City Hospital
RECRUITINGIstanbul, şişli, 34384, Turkey (Türkiye)
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.